Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
about
Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinomaThe role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysisK-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValueCIViC databaseTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerA pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancerRandomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.Lung cancer. 9: Molecular biology of lung cancer: clinical implications.Assessing TP53 status in human tumours to evaluate clinical outcome.The prognostic molecular markers in hepatocellular carcinoma.Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.Mind-mapping for lung cancer: towards a personalized therapeutics approachClinical impact of novel treatment strategies.Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.Adjuvant therapy for resected non-small cell lung cancerRoles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer.How close are we to customizing chemotherapy in early non-small cell lung cancer?Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer.Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer.Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomasImmunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590.Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancerPrognostic value of epidermal growth factor receptor expression in operable non-small cell lung carcinoma.P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection.KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.High expression of cellular retinol binding protein-1 in lung adenocarcinoma is associated with poor prognosis.Personalized medicine and treatment approaches in non-small-cell lung carcinoma.Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancerCombined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients.Biomarkers in lung cancer: from early detection to novel therapeutics and decision makingMolecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized TherapyParameters for individualizing systemic therapy in non-small cell lung cancerTP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis.Prognostic and predictive value of cell cycle deregulation in non-small-cell lung cancer.New and potential clinical applications of KRAS as a cancer biomarker.Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signaturesSelumetinib for the treatment of non-small cell lung cancer.KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.
P2860
Q24649847-08CCC70C-AAE5-457B-9E36-A6FFDE6C326CQ24650902-9B837401-5DC9-4E49-A700-65EC1C6247DAQ26829425-A3D67C97-145C-4ECF-8ED2-913F7433A1EBQ27612411-F1407599-5568-4E9C-8C21-828734F56561Q28396304-FA5FB62F-F438-48B8-B33B-F3CAC8665FD5Q30539299-12667542-BE9C-408C-B4AA-A9A019832074Q33561943-257D7339-16FA-443E-A4C2-9E4D7C30AFEEQ33972805-7429918B-516C-4AE1-A483-E2147E4EB8FBQ34570100-DAF7E3B0-CBA7-4DE5-A18C-CF9208A7AEE9Q34668320-8EC3E670-6C27-4795-B2FC-13144E441F92Q34749852-4EEE7F15-3B4A-41D4-8510-0BAAD4F2E494Q34796086-9BE1D2D6-6C3E-48C3-9C1B-A85057D70B48Q34936052-D2068D0D-6726-4D92-975D-576527C474B2Q34970672-055723C5-92F6-4777-A2D0-8D7482E40E91Q35076202-C50BE4E2-7C06-4845-9E20-E1DF73579082Q35111284-CAADB45F-755E-448F-8226-F263D41CF6DAQ35146944-6EEAC8A5-35CE-4ACA-98E4-72F657E3D823Q35200402-44556185-2A24-4569-BB94-21315101DB1AQ35536290-785C9601-9BF3-4FC4-9F83-EB3E20506CDCQ35592628-A5B8ABD3-696E-4437-B3B6-981365971B57Q35775729-1E632BC6-E5EB-46C7-A604-BAF1F0D1B6C8Q36049618-D527F9DC-0135-4DED-8CA5-2CD9330DB2BFQ36262860-BA33B6DA-C63C-4A88-9AFB-75FE0B1E3324Q36293820-F518B806-6E62-493A-87B7-47CA69B5BBC4Q36308536-5C61E25B-4577-4716-A3E9-8274EC3BE066Q36369197-547FE3AD-7EF0-441A-8098-F40ED5659413Q36430129-07AC92E6-A961-4A50-85F4-E4AF4516F6CAQ36441548-436B3A04-1882-4CF4-900A-C7376C6CB345Q36536565-CF0B7B02-D429-482F-BF3E-7DF6E1FEFE60Q37080964-BC95BAF0-C09B-46C5-AAF7-8DF719E3B8B4Q37342919-6DB8F6B6-C6D0-4BD3-914F-48953599072DQ37347532-8E63AF16-3822-4FDF-85FB-70CD2316020CQ37398845-A73142BB-8AF5-412B-8304-D9F2CEC574DEQ37581666-4B5FBFC9-0637-474B-ACB9-437B6358DEABQ37996270-B83B636D-1740-451C-AD7D-0DC9F878EFC4Q38089885-B94EE50F-33EC-49F3-805C-94C62499153EQ38390072-1FB160E3-E38C-4127-9757-E555B8F551CFQ38663069-FD450341-90D5-462B-A0E3-E12B1FFA49CCQ38669282-15CE8573-98E9-4324-91F0-3C5A49A26453Q38682370-71C78FE9-6ADE-498F-BD49-CFDB5246CBCD
P2860
Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Lack of prognostic significanc ...... ostoperative Adjuvant Therapy.
@ast
Lack of prognostic significanc ...... ostoperative Adjuvant Therapy.
@en
Lack of prognostic significanc ...... ostoperative Adjuvant Therapy.
@nl
type
label
Lack of prognostic significanc ...... ostoperative Adjuvant Therapy.
@ast
Lack of prognostic significanc ...... ostoperative Adjuvant Therapy.
@en
Lack of prognostic significanc ...... ostoperative Adjuvant Therapy.
@nl
prefLabel
Lack of prognostic significanc ...... ostoperative Adjuvant Therapy.
@ast
Lack of prognostic significanc ...... ostoperative Adjuvant Therapy.
@en
Lack of prognostic significanc ...... ostoperative Adjuvant Therapy.
@nl
P2093
P1476
Lack of prognostic significanc ...... ostoperative Adjuvant Therapy.
@en
P2093
D H Johnson
J H Schiller
L Sabatini
M E Hammond
R B Livingston
P304
P356
10.1200/JCO.2001.19.2.448
P407
P577
2001-01-15T00:00:00Z